Johnson & Johnson applies for EU approval of its vaccine

ANKARA

Johnson & Johnson on Tuesday applied for conditional marketing authorization of its COVID-19 vaccine, the European Medicines Agency (EMA) said in a statement.

“EMA’s human medicines committee (CHMP) will assess the vaccine, known as COVID-19 Vaccine Janssen, under an accelerated timetable,” the statement said.

The EMA noted that the decision could be announced in mid-March at the meeting of its Committee for Medicinal Products for Human Use if the vaccine is proven to be safe and effective.

“This is the fourth CMA [conditional market authorization] application for a COVID-19 vaccine since the start of the current pandemic. It comes after EMA’s evaluation of vaccines from BioNTech/Pfizer, Moderna and AstraZeneca. These vaccines are now authorised in the EU and are among the tools Member States are using to combat COVID-19,” said the EMA.

The European Commission should give the final authorization for marketing after the EMA gives its opinion on the vaccine.

The EU, which has a population of 450 million, signed advanced purchase agreements with six firms – Pfizer-BioNTech, Moderna, AstraZeneca, CureVac, Johnson & Johnson, and Sanofi/GlaxoSmithKline – for about 2.3 billion vaccine doses.

ANKARA

Johnson & Johnson on Tuesday applied for conditional marketing authorization of its COVID-19 vaccine, the European Medicines Agency (EMA) said in a statement.

“EMA’s human medicines committee (CHMP) will assess the vaccine, known as COVID-19 Vaccine Janssen, under an accelerated timetable,” the statement said.

The EMA noted that the decision could be announced in mid-March at the meeting of its Committee for Medicinal Products for Human Use if the vaccine is proven to be safe and effective.

The European Commission should give the final authorization for marketing after the EMA gives its opinion on the vaccine.